Galanthamine-d3 (hydrobromide)

CAT: 0804-HY-A0009S-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-A0009S-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Galanthamine-d3 (hydrobromide) is deuterium labeled Galanthamine (hydrobromide) . Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors (nAChRs) . Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD) [1][2][3].
Product Name Alternative
Galantamine-d3 (hydrobromide)
UNSPSC
12352005
Target
Cholinesterase (ChE) ; Isotope-Labeled Compounds; nAChR
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling; Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Solubility
10 mM in DMSO
Smiles
O[C@@H](C=C1)C[C@@](O2)([H])[C@@]31C(C2=C4OC([2H])([2H])[2H])=C(C=C4)CN(C)CC3.Br
Molecular Formula
C17H19D3BrNO3
Molecular Weight
371.28
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Acharya Balkrishna, et al. Anti-Acetylcholinesterase Activities of Mono-Herbal Extracts and Exhibited Synergistic Effects of the Phytoconstituents: A Biochemical and Computational Study. Molecules. 2019 Nov; 24 (22) : 4175.|[3]Balpreet Matharu, et al. Galantamine inhibits beta-amyloid aggregation and cytotoxicity. J Neurol Sci. 2009 May 15;280 (1-2) :49-58.|[4]Debby Van Dam, et al. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) . 2005 Jun;180 (1) :177-90.|[5]Johan Monbaliu, et al. Pharmacokinetics of galantamine, a cholinesterase inhibitor, in several animal species. Arzneimittelforschung. 2003;53 (7) :486-95.|[6]L J Scott, et al. Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60 (5) :1095-122.|[7]Marek Samochocki, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Pharmacol Exp Ther. 2003 Jun;305 (3) :1024-36.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products